The Lupus Research Alliance (LRA) has awarded a total of $2.1 million to five research projects from underrepresented minority scientists focused on the development of tests and treatments for systemic lupus erythematosus (SLE). “We congratulate the inaugural recipients of our Diversity in Lupus Research Awards and look forward to…
Treatment with Benlysta (belimumab) induces meaningful and long-lasting reductions in systemic lupus erythematosus (SLE) disease activity, helping a significant proportion of patients achieve durable remission or a status of low disease activity, a study in a real-world Italian population shows. Patients diagnosed in the prior two years, with…
Rheumatologists, researchers, and patients have joined forces on a global scale to better understand how COVID-19 affects people with rheumatic diseases, including those with systemic lupus erythematosus (SLE). The COVID-19 Global Rheumatology Alliance registry, which had more than 100 cases within one week of launching, “represents…
Lupus significantly affects mobility and the ability to conduct everyday activities, according to a global World Lupus Federation survey. Results of the questionnaire, which surveyed more than 4,000 people from more than 70 countries, were released in conjunction with Lupus Awareness Month, observed each May, and with…
Despite the COVID-19 outbreak, ample online ways exist to mark Lupus Awareness Month, observed each May to call attention to lupus and raise funds for research and education. The national effort is coordinated by the Lupus Foundation of America (LFA), which estimates that…
FFF Enterprises and Bionews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help them connect as a community and continue to manage their health during this time when many are finding themselves alone. Recognized as the nation’s leading supplier of…
While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their homes, one may be a new appreciation of telemedicine. “If something good could come out of this crisis, it’s that…
Lupus Therapeutics, an affiliate of the Lupus Research Alliance (LRA), announced that it is working to design and run a clinical trial into whether hydroxychloroquine and other therapies for systemic lupus erythematosus (SLE) can prevent or ease symptoms of COVID-19 in SLE patients. “This initiative is being done in…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to RemeGen‘s RC18 (telitacicept) to treat people with systemic lupus erythematosus (SLE). A therapy candidate is put on the FDA’s fast track program if it can treat serious conditions and fill an unmet clinical need, either because no…
RemeGen has received $100 million in private financing to continue advancing RC18 (telitacicept), its lead treatment candidate for autoimmune diseases like systemic lupus erythematosus (SLE) now in a pivotal clinical trial. The funding will also support the China-based company’s early stage treatment discovery platform, help expand its manufacturing…